Amazon and Novartis team up on cloud services
pharmafile | December 5, 2019 | News story | Sales and Marketing | Amazon Web Services, Cloud services, Novartis, amazon, pharma, product lines
Novartis is teaming up with Amazon Web Services to utilise its cloud computing technology. The collaboration is designed to overhaul Novartis’s manufacturing, supply and business operations.
Amazon Web Services announced that its technology would “help drive agility, innovation and cost efficiencies across Novartis global business processes and systems.”
Together they will create Insight Centers, which will provide real time data about the company’s distribution and manufacturing operations. It will also allow them to forecast and track production lines, detect potential bottlenecks and make adjustments to avoid them.
Betrand Bodson, the Chief Digital Officer of Novartis, said in a statement: “There is a lot we can learn from the Amazon Web Services team, and while manufacturing is a great starting place, we’re keen to also explore where else we can apply this technology. Using data science and digital technologies to reimagine the way we manufacture medicines is not only at the heart of our transformation, but also core to our ambition to bring innovative medicines to patients faster.”
Novartis has already adopted Amazon’s computer products, using their computer vision equipment to check over their manufacturing lines.
The companies have already begun working on implementing the cloud computing technology, with the first demos to be ready by the end of the year.
This collaboration follows Novartis announcing a partnership with Microsoft back in October, to bring AI tools to every desk across its R&D departments.
Conor Kavanagh
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …
